ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. ("Esperion", "we", "us" or "our") (NASDAQ:ESPR) announced today the pricing of its previously announced underwritten public offering of 56,700,000 shares of its common stock at a public offering price of $1.50 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Esperion. In addition, Esperion granted the underwriters a 30-day option to purchase up to an additional 8,505,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Esperion, are expected to be approximately $85.1 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on January 23, 2024, subject to customary closing conditions.
Jefferies LLC is acting as sole book-running manager for the offering.
Esperion intends to use the net proceeds from the offering of common stock, together with its existing cash and cash equivalents, to fund the ongoing commercialization efforts for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), research and clinical development of current or additional pipeline candidates, working capital, capital expenditures, and general corporate purposes.
A registration statement relating to the offering of common stock has been filed with the Securities and Exchange Commission ("SEC") and was declared effective on April 26, 2022. The offering of common stock is being made ...